Mohammed T. Abou-Saleh

TREATMENT OF LATE-ONSET PSYCHOTIC DISORDERS 525effects reported included dyspepsia, transient somnolence, constipation,nausea and abdominal pain 49 . Ziprasidone wasassociated with a lower incidence of EPS and postural hypotension,with no weight gain or laboratory abnormalities 49 .REFERENCES1. American Psychiatric Association: Diagnostic and Statistical Manualof Mental Disorders, 4th edn. Washington, DC: American PsychiatricAssociation, 1994.2. Myers JK, Weissman MM, Tischler G. Six month prevalence ofpsychiatric disorders in three communities. Arch Gen Psychiat 1984;41: 959–70.3. Junginger J, Phelan E, Cherry K et al. Prevalence of psychopathologyin elderly persons in nursing homes and in the community. HospCommun Psychiat 1993; 44: 381–3.4. Skoog I, Nilsson L, Landahl S et al. Mental disorders and the use ofpsychotropic drugs in an 85-year-old urban population. IntPsychogeriat 1993; 5: 33–48.5. Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R. SPECTfindings on psychosis in Alzheimer’s disease. Am J Psychiat. 1995;152(10): 147–5.6. Burke D, Sushmita S. Early intervention in schizophrenia in theelderly. Aust NZ J Psychiat 1998; 32: 809–14.7. Lindamer LA, Lohr JB, Harris MJ et al. Gender related clinicaldifferences in older patients with schizophrenia. J Clin Psychiat 1999;60: 61–7.8. Lacro JP, Jeste DV. Geriatric psychosis. Psychiat Qu 1997; 68: 247–60.9. Harris MJ. Psychosis in late life spotting new-onset disorders in yourelderly patients. Postgrad Med 1997; 102: 139–42.10. Ciompi L. Catamnestic long-term study on the course of life andaging of schizophrenics. Schizophren Bull 1980; 6: 606–18.11. Kim KY, Goldstein MZ. Treating older adults with psychoticsymptoms. Psychiat Serv 1997; 48: 1123–6.12. Streim JE, Oslin D, Katz IR, Parmelee PA. Lessons from geriatricpsychiatry in the long-term care setting. Psychiat Q 1997; 68(3): 281–307.13. Zayas E, Grossberg GT. The treatment of psychosis in late life. J ClinPsychiat 1998; 59(5): 5–10.14. Jeste DV, Harris MJ, Krull A et al. Clinical and neuropsychologicalcharacteristics of patients with late-onset schizophrenia. Am JPsychiat 1995; 152: 722–30.15. Ohi G, Kai I, Ichikawa S et al. Psychotic manifestation in the bed-fastelderly. Hum Ergol 1989; 18: 237–40.16. Eastwood MR, Corbin SL, Reed M et al. Acquired hearing loss andpsychiatric illness: an estimate of prevalence and comorbidity in ageriatric setting. Br J Psychiat 1985; 147: 552–6.17. Caliguiri MP, Lacro JP, Jeste DV. Incidence and predictors of druginducedparkinsonism in older psychiatric patients treated with verylow doses of neuroleptics. J Clin Psychopharmacol 1999; 19: 322–8.18. Caliguiri MP, Rockwell E, Jeste DV. Extrapyramidal side effects inpatients with Alzheimer’s disease treated with low-dose neurolepticmedication. Am J Geriat Psychiat 1998; 6: 75–82.19. Tison F, Lecaroz J, Letenneur L et al. Parkinsonism and exposure toneuroleptic drugs in elderly people living in institutions. ClinNeuropharmacol 1999; 22: 5–10.20. Caliguiri MP, Lacro JP, Rockwell E et al. Incidence and risk factors forsevere tardive dyskinesia in older patients. Br J Psychiat 1997; 171: 148–53.21. Woerner MG, Alvir JA, Saltz BL et al. Prospective study of tardivedyskinesia in the elderly: rates and risk factors. Am J Psychiat 1998;155: 1521–8.22. Caliguiri MP, Lohr JB. Instrumental motor predictors of neurolepticinducedparkinsonism in newly medicated schizophrenia patients. JNeuropsychiat Clin Neurosci 1997; 9: 562–7.23. Johnson V, Bruxner G. Neuroleptic malignant syndrome associatedwith olanzapine. Aust NZ J Psychiat 1998; 32: 884–6.24. Brown FW. Late-life psychosis: making the diagnosis and controllingsymptoms. Geriatrics. 1998; 53(12): 26–8, 37–8, 41–2.25. Herst L, Powell G. Is clozapine safe in the elderly? Aust NZ J Psychiat1997; 31: 411–17.26. Chengappa KNR, Baker RW, Kreinbrook SB et al. Clozapine use infemale geriatric patients with psychoses. J Geriat Psychiat Neurol1995; 8: 12–15.27. Salzman C, Vaccaro B, Lieff J et al. Clozapine in older patients withpsychosis and behavioural disruption. Am J Geriat Psychiat 1995; 3: 26–33.28. Pitner JK, Mintzer JE, Pennypacker LC et al. Efficacy and adverseeffects of clozapine in four elderly psychotic patients. J Clin Psychiat1995; 56: 180–5.29. Briffa D, Meehan T. Weight changes during clozapine treatment. AustNZ J Psychiat 1998; 32: 718–21.30. Sajatovic M, Ramirez LF, Garver D et al. Clozapine therapy forolder veterans. Psych Serv 1998; 49: 340–4.31. Sajatovic M, Ramirez L. Clozapine therapy in patients withneurologic illness. Int J Psychiat Med. 1995; 25(4): 331–44.32. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, MegensAA, Meert TF. Pharmacology of risperidone (R 64 766), a newantipsychotic with serotonin-S2 and dopamine-D2 antagonisticproperties. J Pharmacol Exp Ther. 1988; 244(2): 685–93.33. Sajatovic M, Ramirez LF, Vernon L et al. Outcome of risperidone inthe treatment of elderly patients with chronic psychosis. Int J PsychiatMed 1996; 57(3): 39–45.34. Katz IR, Jeste DV, Mintzer JE et al. Comparison of risperidone andplacebo for psychosis and behavioral disturbances associated withdementia: a randomized, double-blind trial. J Clin Psychiat 1999; 60:107–15.35. Grossberg GT, Manepalli J. The older patient with psychoticsymptoms. Psychiat Serv. 1995; 46(1): 55–9.36. Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy ofrisperidone treatment for psychoses associated with schizophrenia,schizoaffective disorder, bipolar disorder, or senile dementia in 11geriatric patients: a case series. J Clin Psychiat. 1995; 56(11): 514–8.37. Madhusoodanan S, Brecher M, Brenner R, Kasckow J, Kunik M,Negron AE, Pomara N. Risperidone in the treatment of elderly patientswith psychotic disorders. Am J Geriatr Psychiat. 1999; 7(2): 132–8.38. Madhusoodanan S. Risperidone and Cognitive Functioning inElderly Schizophrenic Patients (Dr. Madhusoodanan comments).Am J Geriatr Psychiat. 2000; 8(2): 178–9.39. Fischer P, Tauscher J, Kufferle B. Risperidone and tardive dyskinesiain organic psychosis. Pharmacopsychiatry. 1998; 31(2): 70–1.40. Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatientclinics at six veterans affairs hospitals. Psychiat Serv 1999; 50(2): 163–8.41. Zarate CA, Baldessarini RJ, Siegel AJ et al. Risperidone in theelderly: a pharmacologic study. J Clin Psychiat 1997; 58: 311–17.42. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine. Areview. Br J Psychiatry Suppl. 1999; (38): 52–8.43. Street JS, Tollefson GD, Tohen M et al. Olanzapine for psychoticconditions in the elderly. Psychiat Ann 2000; 30(3): 191–6.44. Tollefson GD, Beasly CM, Tran PV et al. Olanzapine vs. haloperidolin the treatment of schizophrenia and schizoaffective andschizophreniform disorders: results of an international collaborativetrial. Am J Psychiat 1997; 154: 457–65.45. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, HamiltonS. Olanzapine versus placebo: results of a double-blind, fixed-doseolanzapine trial. Psychopharmacology (Berl). 1996; 124(1–2): 159–67.46. McManus DQ, Arvantis LA, Kowalcyk BB. Quetiapine, a novelantipsychotic: experience in elderly patients with psychotic disorders.J Clin Psychiat 1999; 60: 292–8.47. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-Term useof quetiapine in elderly patients with psychotic disorders. Clin Ther.2000; 22(9): 1068–84.48. Tariot PN, Salzman C, Yeung PP et al. Clinical improvement andtolerability is maintained long term in elderly patients with psychoticdisorders treated with seroquel (quetiapine). Eur Neuropsychopharmacol1999; 9(5): S268.49. Keck P, Buffenstein A, Ferguson J et al. Ziprasidone 40 and 120 mg/dayin the acute exacerbation of schizophrenia and schizoaffective disorder: a4 week placebo-controlled trial. Psychopharmacology 1998; 140: 173–84.50. Daniel DG, Zimbroff DL, Potkin SG et al. Ziprasidone 80 mg/dayand 160 mg/day in the acute exacerbation of schizophrenia andschizoaffective disorder: a 6-week placebo-controlled trial.Neuropsychopharmacology 1999; 20(5): 491–505.51. Gregory C, McKenna P. Pharmacological management ofschizophrenia in older patients. Drugs Aging 1994; 5: 254–62.52. McKeith I, Fairbain A, Perry R et al. Neuroleptic sensitivity in patientswith senile dementia of the Lewy body type. Br Med J 1992; 305: 673–8.53. Schneider LS. Pharmacologic management of psychosis in dementia.J Clin Psychiat 1999; 60(8): 54–60.